These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38377098)

  • 1. Relationship between biologic modifying agents and development of latent tuberculosis in pediatrics.
    Bedir Demirdag T; Ozkaya Parlakay A; Aydin F; Tugcu GD; Santaflıoglu B; Kanik Yuksek S; Gulhan B; Cinel G; Celikel Acar B
    J Infect Dev Ctries; 2024 Jan; 18(1):116-121. PubMed ID: 38377098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents.
    So H; Yuen CS; Yip RM
    Hong Kong Med J; 2017 Jun; 23(3):246-50. PubMed ID: 28126971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests.
    Malaviya AN; Aggarwal VK; Rawat R; Baghel S; Thakran R; Zaheer Q; Garg S; Kapoor S
    Int J Rheum Dis; 2018 Aug; 21(8):1563-1571. PubMed ID: 29345081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain.
    Calzada-Hernández J; Anton J; Martín de Carpi J; López-Montesinos B; Calvo I; Donat E; Núñez E; Blasco Alonso J; Mellado MJ; Baquero-Artigao F; Leis R; Vegas-Álvarez AM; Medrano San Ildefonso M; Pinedo-Gago MDC; Eizaguirre FJ; Tagarro A; Camacho-Lovillo M; Pérez-Gorricho B; Gavilán-Martín C; Guillén S; Sevilla-Pérez B; Peña-Quintana L; Mesa-Del-Castillo P; Fortuny C; Tebruegge M; Noguera-Julian A
    Eur J Pediatr; 2023 Jan; 182(1):307-317. PubMed ID: 36335186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis risk in the biologic era: tuberculin skin test conversion rates in children with rheumatologic diseases.
    Özlü C; Türkuçar S; Asrak HK; Dündar HA; Ünsal ŞE; Belet N
    Turk J Pediatr; 2021; 63(6):978-985. PubMed ID: 35023647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
    Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
    J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.
    Calzada-Hernández J; Anton-López J; Bou-Torrent R; Iglesias-Jiménez E; Ricart-Campos S; Martín de Carpi J; ; Torrente-Segarra V; Sánchez-Manubens J; Giménez-Roca C; Rozas-Quesada L; Juncosa-Morros MT; Fortuny C; Noguera-Julian A
    Pediatr Rheumatol Online J; 2015 Dec; 13():54. PubMed ID: 26635208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy.
    Ramos GP; Stroh G; Al-Bawardy B; Faubion WA; Papadakis KA; Escalante P
    Inflamm Bowel Dis; 2018 Sep; 24(10):2272-2277. PubMed ID: 29718223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of single and dual latent tuberculosis screening strategies before biologic and targeted therapy in patients with rheumatic diseases: a retrospective cohort study.
    Tang I; So H; Luk L; Wong V; Pang S; Lao V; Yip R
    Hong Kong Med J; 2020 Apr; 26(2):111-119. PubMed ID: 32245912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study.
    Ho CS; Feng PI; Narita M; Stout JE; Chen M; Pascopella L; Garfein R; Reves R; Katz DJ;
    Lancet Infect Dis; 2022 Jan; 22(1):85-96. PubMed ID: 34499863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.
    Chang B; Park HY; Jeon K; Ahn JK; Cha HS; Koh EM; Kang ES; Koh WJ
    Clin Rheumatol; 2011 Dec; 30(12):1535-41. PubMed ID: 21556777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TST, QuantiFERON-TB Gold test and T-SPOT.TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy.
    Sargın G; Şentürk T; Ceylan E; Telli M; Çildağ S; Doğan H
    Tuberk Toraks; 2018 Jun; 66(2):136-143. PubMed ID: 30246657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordance between TST and QFT-TBGold Plus for Latent Tuberculosis Screening among Under-Five Children: An Interim Analysis.
    Surve S; Bhor V; Naukariya K; Begum S; Munne K; Tipre P; Sutar N; Jaiswal A; Bhonde G; Chauhan S; Shah I
    J Trop Pediatr; 2021 Dec; 67(6):. PubMed ID: 34904674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for latent tuberculosis in Norwegian health care workers: high frequency of discordant tuberculin skin test positive and interferon-gamma release assay negative results.
    Gran G; Aßmus J; Dyrhol-Riise AM
    BMC Public Health; 2013 Apr; 13():353. PubMed ID: 23590619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis.
    Auguste P; Tsertsvadze A; Pink J; Court R; McCarthy N; Sutcliffe P; Clarke A
    BMC Infect Dis; 2017 Mar; 17(1):200. PubMed ID: 28274215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.